Aventis's Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with ...

The FDA has approved Merilog, the first-ever rapid-acting insulin biosimilar for diabetes treatment that helps manage blood ...

The FDA has approved Merilog (insulin-aspart-szjj), a biosimilar to Novolog, to improve glycemic control in patients with diabetes mellitus.

The regulatory action makes Merilog the first rapid-acting insulin biosimilar to gain FDA approval. According to the federal agency, the approval includes both a prefilled pen and a multi-dose vial, ...

The approval is for both a 3 milliliter or mL single-patient-use prefilled pen and a 10 mL multiple-dose vial. As a rapid-acting human insulin, Merilog helps to lower mealtime blood sugar spikes ...

multiple-dose vial,” USFDA said in a statement. Merilog is the third insulin biosimilar product approved by the FDA and joins the two long-acting insulin biosimilar products approved in 2021 by ...

As a rapid-acting insulin, Merilog helps to lower mealtime blood sugar spikes to improve control of blood sugar in people with diabetes. The approval is for both a 3 milliliter (mL) single-patient-use ...

dosage and administration, cost, and place in therapy of insulin detemir are reviewed. Summary: Insulin detemir is a long-acting, neutral, and soluble insulin analogue with a lower within-subject ...

Sanofi’s Admelog (insulin lispro) is approved in type 1 and type 2 diabetes as a follow-on drug to Humalog, a rapid-acting insulin that is Lilly’s top selling drug, bringing in almost $700 ...

NovoPen ®, the first insulin pen injector, was introduced in 1985. This article reviews the published evidence over two decades of use of the NovoPen ® family of injection devices in diabetes ...